Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography

Q: What is the clinical evidence from this study?

Study design: Letter. Population: Sickle cell disease and HIV infection. Intervention: Tricuspid regurgitant jet velocity ≥2.5 m/s (pulmonary artery systolic pressure >30 mm Hg). Primary outcome: death (rate ratio 10.1, 95% CI 2.2-47.0, p=<0.001).

Charles A. Herzog

doi:10.1001/jama.299.17.2023

May 6, 2008JAMA

Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography

View at Publisher

Ask AI

Bookmark

Share

PICO

P

Population

Cohorts of patients with sickle cell disease (median age 34 years) and HIV infection (median age 47 years) evaluated for pulmonary artery systolic pressure.

E

Exposure / Comparator

Tricuspid regurgitant jet velocity ≥2.5 m/s (pulmonary artery systolic pressure >30 mm Hg)

O

Primary Outcome

death — rate ratio 10.1 (2.2-47.0), p=<0.001

Main Result

Relative Risk: 10.1 (95% CI 2.2–47)

p-value: p=<0.001

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Charles A. Herzog (2008) conducted a letter in Sickle cell disease and HIV infection. Tricuspid regurgitant jet velocity ≥2.5 m/s (pulmonary artery systolic pressure >30 mm Hg) was evaluated on death (rate ratio 10.1, 95% CI 2.2-47.0, p=<0.001).

synapsesocial.com/papers/6a6979ea24a3c63b501a3573 https://doi.org/10.1001/jama.299.17.2023

View at Publisher

Ask AI

Bookmark

Share

Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography

PICO

Main Result

Abstract

Discussion

Cite This Study

Incidence of Adverse Events Associated With Use of Perflutren Contrast Agents for Echocardiography

PICO

Main Result

Abstract

Discussion

Cite This Study

Keep reading

Keep reading